Drug Profile
LMB 100
Alternative Names: anti-MSLN-PE24-cFP; LMB100; RG7787; RO6927005Latest Information Update: 08 Jul 2023
Price :
$50
*
At a glance
- Originator Roche
- Developer National Cancer Institute (USA); Roche
- Class Antineoplastics; Drug conjugates; Immunoglobulin fusion proteins; Immunotoxins; Proteins
- Mechanism of Action Megakaryocyte potentiating factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Mesothelioma; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
Most Recent Events
- 02 Jun 2023 Efficacy and adverse events data from a phase-I trial in Solid tumours presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
- 19 May 2022 National Cancer Institute plans a phase I trial in Solid tumours (Late-stage disease, Second-line therapy or greater, Metastatic disease) in USA (IV) (NCT05375825)
- 04 Jun 2021 Efficacy, safety and pharmacokinetics data from phase I trials in Solid tumours presented at 57th Annual Meeting of the American Society of Clinical Oncology (ASCO-2021)